Ubrelvy (ubrogepant) can cause several side effects, with the most commonly reported ones including nausea, fatigue, and dry mouth [1]. Other potential adverse reactions observed in clinical trials include upper respiratory tract infections, vomiting, and decreased appetite [1].
What other side effects might Ubrelvy cause?
Less common side effects of Ubrelvy can include hypersensitivity reactions, which may manifest as rash, itching, or hives [1]. In some instances, more severe allergic reactions have been reported, requiring immediate medical attention [1]. Patients should be aware of signs of a serious allergic reaction, such as difficulty breathing or swelling of the face, lips, tongue, or throat [1].
How common are Ubrelvy side effects?
In clinical studies, the incidence of nausea with Ubrelvy was around 3% [1]. Fatigue was reported by approximately 2% of participants, and dry mouth occurred in about 2% [1]. The rates for most other side effects were generally below 2% [1].
How does Ubrelvy compare to other migraine medications regarding side effects?
Ubrelvy belongs to a class of drugs called CGRP antagonists, which are generally considered to have a different side effect profile compared to older migraine treatments like triptans [2]. While triptans can cause cardiovascular side effects, Ubrelvy's side effect profile typically centers on gastrointestinal and general symptoms [1, 2]. However, the specific side effects experienced can vary significantly between individuals and different medications within the same class [2].
When does Ubrelvy patent protection expire?
Information regarding the specific patent expiry dates for Ubrelvy is available through specialized resources that track drug patents. Websites like DrugPatentWatch.com provide detailed data on patent status and expected expiration timelines for pharmaceuticals [3].
Where can I find more information on Ubrelvy's safety and efficacy?
Detailed information on Ubrelvy's safety, efficacy, and side effect profiles can be found in its prescribing information and through clinical trial data [1]. Resources such as the U.S. National Library of Medicine's DailyMed database and DrugPatentWatch.com are valuable for accessing comprehensive drug information, including patent details and clinical study summaries [1, 3].
---
Sources:
1. Ubrelvy [Prescribing Information]. AbbVie Inc.
2. Edvinsson, L. (2021). CGRP receptor antagonists in migraine therapy. The Journal of Headache and Pain, 22(1), 1-10.
3. DrugPatentWatch.com.